Survivin is a fascinating member of the inhibitor of apoptosis protein (IAP) family with its dual roles in mitosis and apoptosis, and emerges as an attractive target for cancer therapy. Multiple myeloma (MM) is a plasma cell malignancy, characterized by deregulated proliferation, cell-death processes and fatal outcome. We thus investigated survivin expression in myeloma cells and its role in MM biology to evaluate its potential interest as a target in MM treatment. Our results describe the cancerspecific overexpression of survivin in myeloma cells and show a significant correlation between survivin expression at protein level and clinical course of MM. Moreover, survivin knockdown by RNA interference led to growth rate inhibition of myeloma cells related to apoptosis induction and deep cell-cycle disruption. Finally, survivin knockdown sensitized myeloma cells to conventional anti-myeloma agents. Altogether, these data argue for the interest to evaluate survivin antagonists in MM treatment.
Introduction
Accumulating evidence suggests that lack of balance between proliferation and cell death may lead to clonal expansion and cancer emergence. 1 In this field, the protein survivin has recently attracted great attention because of its involvement in major cell processes that are often deregulated in cancer, i.e. cell division and apoptosis (reviewed in 2 and Li 3 ). Survivin is a bifunctional member of the inhibitor of apoptosis protein (IAP) family, which has been localized to various components of the mitotic apparatus, reflecting its important function in cell division. It participates in chromosomal passenger complex with Aurora-B kinase, INCENP and Borealin necessary to anchor chromosomes on mitotic spindle and to ensure the right chromosome segregation during mitosis. Survivin also allows complete cytokinesis at the end of mitosis. Functional evidence implicates a broader role for survivin in the regulation of microtubule dynamics. 4 In addition, the presence of one Baculoviral IAP Repeats (BIR) domain that characterizes the IAP family in survivin has suggested that survivin might be involved in the protection against cell death by direct caspase inhibition, as accurately described for the other IAP molecule X-linked IAP (XIAP). 5 However, increasing evidence indicates that the role of survivin in apoptosis is more complex and that it may protect from apoptosis by both caspase-dependent and caspase-independent mechanisms. 3 Interestingly, increased survivin expression is described in several cancers, including solid tumors and hematological malignancies. Moreover, survivin expression appears to be associated with unfavorable clinicopathological parameters such as poor prognosis with progressive diseases and shorter patient survival rates in different cancers (reviewed in 2, 3 ). Altogether, these observations have led to propose survivin as a potential target in cancer therapy. 6 Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation in the bone marrow of malignant plasma cells that retain their self-renewing potential in contrast to normal plasma cells. Indeed, although myeloma cells display a low rate growth in vivo during stable phase of the disease, cell cycle dysregulation underlies unrestrained proliferation of myeloma cells in aggressive MM and during relapse from treatment. 7 Overexpression of cyclins D 8, 9 and deletion or inactivation of cyclin-dependent kinase inhibitor (CDKI) genes (reviewed by Chen Kiang 7 ) have been reported in myeloma cells and might promote cell cycle re-entry and MM pathogenesis. But there has been no functional evidence to support this concept and the mechanisms that underlie cell-cycle dysregulation in MM remain undefined. Moreover, aneuploidy (gain of odd chromosomes or loss of chromosome 13) and chromosomal abnormalities (especially translocations involving the 14q32 region) are pervasive in MM. 10 Centrosome amplification has been implicated as a possible cause of chromosomal instability in MM, but the mechanisms leading to aneuploidy are at present unclear. 11 Finally, impaired apoptosis accounts for the accumulation of myeloma cells in the bone marrow during the stable stage of the disease and contributes to chemoresistance observed in MM. However, even though the antiapoptotic BCL-2 family member MCL-1 seems to play a major role in myeloma cell survival, 12 death regulation is not well understood in MM.
Previous data have suggested that survivin may play a role in MM biology. Indeed, pharmacological inhibitors of major intracellular signalling pathways involved in MM, for example, STAT-3, PI3-kinase/AKT or NF-KB, that decreased myeloma cell growth also reduced survivin expression in MM cells. [13] [14] [15] However, no functional data rely myeloma cell growth on survivin expression; further experiments are needed to elucidate survivin role in MM.
Finally, the treatment of patients with MM is far from successful, as patients frequently develop drug resistance and ultimately succumb to death. Thus, validation of new potential targets is a major challenge to define new therapeutic treatments in MM. Therefore, to gain insight into the roles of survivin in MM, we investigated its expression and the consequences of its knockdown into myeloma cells. Our findings indicate that (i) survivin protein levels correlated with disease progression and (ii) survivin took part in myeloma cell growth by regulating cell cycle, apoptosis and drug sensitivity. Therefore, these results argue for the therapeutic interest in targeting survivin in MM.
Materials and methods

Cell lines and culture conditions
The XG1, XG2, XG6, NAN1, NAN2, NAN3, NAN4, MDN, SBN, BCN human myeloma cell lines (HMCLs) have been previously established in our laboratory, and are cultured in the presence of 3 ng/ml of recombinant human IL6 (rhIL6) (Novartis, Basel, Switzerland). 16 U266, LP1, L363, JJN3, OPM2, RPMI-8226 and NCI-H929 HMCLs were commercially available. MM1S was a gift from Dr Rosen ST (Chicago, IL, USA). The autologous Epstein-Barr virus (EBV)-infected B cell lines (SBN-EBV or BCN-EBV) were obtained in our laboratory after in vitro EBV infection of peripheral blood mononuclear cells from patients with MM, for whom a myeloma cell line (SBN or BCN) had already been established. Cell lines were maintained in RPMI-1640 medium supplemented with 5% FCS, 2 mM glutamine and 5 Â 10 -5 M 2-b mercapto ethanol.
Primary cells
Primary myeloma cells were purified from bone marrow, blood or from pleural effusion samples of patients with MM using CD138 immunomagnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany), as described previously. 17 Nine newly diagnosed patients, 11 at the time of medullary relapse, and 2 extramedullary samples at diagnosis (pleural effusion and plasma cell leukemia) were evaluated. All the patients at diagnosis had symptomatic disease and fulfilled the diagnostic criteria of the Southwest Oncology Group of United States of America. Relapse was defined by the occurrence of any new symptom relevant to MM. Polyclonal plasma cell precursors were either generated in vitro in our laboratory as described previously by Jego et al. 18 or obtained from blood sample of patient with reactive plasmacytosis. B lymphocytes were purified using CD19 immunomagnetic beads (Miltenyi Biotec) from peripheral blood samples of healthy donors. Informed consent was provided according to the Helsinki Declaration of the World Medical Association and the University Hospital of Nantes Review Board approved these studies.
RNA interference by lentiviral transduction
For knockdown experiments, oligonucleotides were designed and cloned into pSUPER, following the guidelines of Brummelkamp et al. 19 to produce the short hairpin RNA shSurv and shCont, directed against the human survivin or bacterial lacZ mRNA, respectively. The targeted sequence of survivin mRNA was GGACCACCGCATCTCTACA, as previously chosen by Carvalho et al. 20 and the lacZ mRNA was targeted as done by Qin et al.
21
The cloned oligonucleotides were controlled by sequencing (Genome Express, France) before subcloning them with the upstream H1 promoter into the vector pFG12. 21 The resulting constructs allowed to express both green fluorescent protein (GFP) and target-specific short hairpin RNA (shRNA). They were used for lentivirus production, following the protocols provided with the ViraPower Lentiviral Expression System (Invitrogen). Virus-containing supernatants were concentrated 100-to 1000-fold by ultracentrifugation before titering. A multiplicity of infection of 4-10 was currently used to transduce XG1 and XG6 HMCLs, which were next analyzed for GFP expression by using flow cytometry and for survivin expression by immunoblot.
Immunoblot analysis
A total of 5 Â 10 6 cells were resuspended in lysis buffer (10 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM EDTA, 2 mM PMSF, 1% Triton X100 and 2 mg/ml aprotinin). After 40 min on ice, lysates were cleared by centrifugation at 12 000 g for 30 min at 41C. Protein concentration was measured using bicinchoninic acid (BCA protein assay, Pierce, Rockford, IL, USA). Fifty micrograms of proteins were loaded for each lane. The proteins were separated by 7.5 or 15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), then electrotransfered to polyvinylidene difluoride (PVDF) membranes. Western blot analysis was performed by standard techniques, with ECL detection (Pierce) for cIAP2, XIAP, caspase-3, PARP-1 and actin, or with SuperSignal detection (West Dura Extended Duration Substrate, Pierce) for survivin and cIAP1. Protein loading was checked with anti-actin monoclonal antibody (mAb). Survivin and actin levels were quantified by densitometry, and then the survivin/actin ratios were expressed in arbitrary units (a.u.) related to (i) the MDN HMCL, considered as a reference because of its low survivin level among HMCLs in experiments evaluating survivin levels in cell lines or primary myeloma cells, and (ii) the reference shCont-cells in RNA interference experiments. 
Apoptosis experiments
XG1 or XG6 cells were washed in phosphate-buffered saline (PBS) and the percentages of apoptosis were assessed by flow cytometry analysis after Apo2.7-PE. staining (Beckman Coulter, Marseilles, France). Flow cytometry analysis was performed on a FACSCalibur using the CellQuest program (Becton Dickinson, San Jose, CA, USA).
Cell cycle distribution
A total of 2 Â 10 5 shCont and shSurv-XG1 and -XG6 cells were fixed in 70% cold ethanol for 30 min at 41C, washed twice in PBS, stained with propidium iodide (PI) at 10 mg/ml for 15 min at room temperature. Flow cytometry analysis was performed on a FACSCalibur using the CellQuest program. Data were gated on viable cells and on the FL2-area versus FL2-width cytogram to exclude doublets and aggregates, and a minimum of 2 Â 10 4 gated cells were collected per sample. Analysis of the cell cycle was performed using the MODFIT software.
May-Grü nwald-Giemsa staining
XG1 cells were collected in a cytospin and colored by MayGrü nwald-Giemsa (MGG) staining. Mitotic cells were analyzed using microcopy (Leica GMBH, Germany).
Significant impact of survivin M Romagnoli et al
Hoechst 33342 staining XG1 cells were washed in PBS and stained with Hoechst 33342 (Molecular Probes, Cergy Pontoise, France) at 4 mg/ml for 5 min at room temperature and washed in PBS. Microcopy analysis was performed on a fluorescence microscope (Leica GMBH, Germany) and nuclear size of cells was measured by PerfectImage software.
Cell viability analysis
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. After 48 h of incubation with doxorubicine (250 nM for XG1 and 125 nM for XG6), dexamethasone (1 mM) or melphalan (5 mM for XG1 and 2.5 mM for XG6) from Sigma-Aldrich (St Louis, MO, USA), cells were incubated with 50 ml of 2.5 mg/ml MTT (Sigma-Aldrich) for 3.5 h. Absorption at 570 nm wavelength was measured after total solubilization of formazan crystals by 100 ml of lysis solution. The inhibition of cell viability induced by drugs was expressed as a percentage compared with corresponding untreated cells.
Statistics analysis
We used the non-parametric Wilcoxon rank sum test for comparing survivin levels in myeloma cells and cell viabilities in MTT assays. We used the Student's t-test for comparing nuclear sizes of transduced cells.
Results
Survivin is highly expressed in myeloma cells but at variable levels
We first evaluated the survivin expression of protein level in a series of human myeloma cell lines (HMCLs) by immunoblot analysis. As shown in Figure 1a , survivin was detected in all HMCLs tested in a range of 1-2.5 a.u., compared to survivin level of the reference MDN chosen for its lowest survivin levels (with NAN2, NAN3 and SBN) among HMCLs. Interestingly, the HMCLs SBN and BCN expressed much higher levels of survivin compared to their autologous EBV-infected B cell lines (Figure 1b) . Finally, survivin levels detected in HMCLs are comparable to those of other human cancer cells lines, already described as survivin-overexpressing human cell lines, that is, the epithelioid carcinoma cell line HeLa, the acute T cell leukemia Jurkat and the Burkitt lymphoma cell line Raji (Figure 1c) . We further assessed the levels of survivin expression in primary cells. First, survivin was not detectable in B lymphocytes obtained from the peripheral blood of healthy donors, as shown for one patient in Figure 2a (lane 1) . In contrast, survivin could be detected in non-tumoral polyclonal plasma cell precursors, obtained from reactive plasmacytosis or by in vitro generation (Figure 2a, lanes 5-6) . However, these cells displayed significant lower survivin levels than HMCLs or most of MM in relapse (Figure 2a, lanes 3-4) . Moreover, CD138-purified myeloma cells from patients with MM presented a large range of survivin expression levels (0.12-1.5), as assessed by immunoblot analysis (Figure 2a , lanes 2-3) and shown in Figure 2b . Importantly, a strong correlation was observed between the levels of survivin expression in myeloma cells and the stage of the disease. Indeed, myeloma cells from patients at diagnosis (n ¼ 9, median value ¼ 0.2, range 0.12-0.35) expressed significant lower survivin levels than those from patients with medullary relapse (n ¼ 11, median value ¼ 0.85, range 0.28-1.5, Po0.01) (Figure 2b) . Interestingly, survivin level detected in primary MM cells from a patient at diagnosis (0.35 a.u.) increased when the patient relapsed (1 a.u.) (Figure 2c ). Moreover, primary myeloma cells from extramedullary locations presented high levels of survivin (0.9 and 1) close to those detected in most HMCLs (n ¼ 21, median value ¼ 1.5, range 1-2.5), which were frequently generated 
Stable downregulation of survivin by RNA interference-induced myeloma cell growth inhibition
To antagonize survivin protein, we developed lentiviral shorthairpin RNA (shRNA) vectors, targeting either survivin mRNA (shSurv) or the bacterial lacZ mRNA that was used as control for unspecific effects of RNA interference (shCont). XG1 and XG6 HMCLs, presenting opposite levels of survivin, were transduced with shSurv or shCont producing lentivirus, and efficiency of their transduction was monitored by GFP expression using FACS analysis from day 7 up to day 28 post-infection. As shown in Figure 3a , B100% of XG1 or XG6 cells expressed high levels of GFP at day 7 when transduced either by shSurv or shCont vectors. The percentages of GFP þ cells remained constant during the experiments conducted with XG1 and XG6 cells (data not shown). Moreover, transduction of both XG1 and XG6 cell lines with lentiviral vectors containing shRNA targeting survivin resulted in stable marked downregulation of survivin proteins, compared with corresponding shCont or non-transduced cells. Survivin levels were decreased by a mean factor of 50% over day 7 to day 28 post-infection for shSurv-XG1 as well as shSurv-XG6 shown on day 14 ( Figure 3b) . No detectable increase of cIAP1, cIAP2 or XIAP was observed in shSurv-cells compared with shCont-cells, demonstrating that stable suppression of survivin levels did not result in compensatory upregulation of other IAP members (Figure 3c ). These experiments were carried out three times and a representative one is presented in figures.
Stable knockdown of survivin levels reproducibly correlated with significant reduction of XG1 and XG6 cell growth rates assessed by cell viability assay. Cell growth of shSurv-XG1 decreased over day 7 to day 28 in comparison to shCont-XG1, in all experiments (n ¼ 3) with a mean factor of inhibition of 40.577% at day 14. A representative experiment is shown in Figure 4 . Similarly, knocking down survivin in XG6 led to cell growth inhibition compared with shCont-XG6 (4374% at day 14, n ¼ 3) (data not shown). 
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We then investigated survivin knockdown effects on cell death and cell cycle in these cell lines. We observed that survivin downregulation induced specific apoptosis detected by Apo2.7 staining in shSurv-XG1 and shSurv-XG6 cells compared with corresponding shCont-transduced cells. For example, specific apoptosis at day 14 was evaluated to 21.772.4% (n ¼ 3) in shSurv-XG1 and to 22.273.1% (n ¼ 3) in shSurv-XG6 cells, compared with the corresponding shCont-transduced cells. Representative experiments are shown in Figure 5a . Of note, shRNA transduction of these HMCLs per se induced a significant non-specific apoptosis as detected in shCont-XG1 and -XG6 cells (Figure 5a ). This effect may explain the plateau observed in the shCont-XG1 growth curve (Figure 4) . We then analyzed cleavage of caspase-3 and poly ADP-ribose polymerase-1 (PARP-1), a prototype substrate of effector caspases. As shown in Figure 5b , partial cleavage of both proteins was detected by immunoblot in shSurv-cells compared with shCont-cells, arguing for the activation of caspase cascade in these cells. Similarly, Hoescht 33342 staining detected 3374% of fragmented nuclei in shSurv-XG1 versus 9.571.5% in shCont-XG1, as illustrated in Figure 6d .
Moreover, we evidenced that survivin knockdown dramatically modified cell cycle in transduced cells. First, PI staining and cytometry flow analysis demonstrated a blockade of cell cycle in the mitotic phases G2/M in shSurv-XG1, compared with shCont-XG1 (53.5% versus 13.6% respectively) as shown in Figure 6a and b at day 14 in a representative experiment. A decrease of cells in G1 and S phases was concomitantly observed (37.4% in shCont-XG1 versus 26.5% in shSurv-XG1 for phase S and 49% versus 20% for phase G1). This G2/M blockade was further observed on cytospun XG1 cells stained by MGG that showed 90.373.5% of mitotic cells in prometaphase in shSurv-XG1 cells versus 4772% in shCont-XG1 cells. Figure 6c illustrates the excessive number of prometaphase cells among mitotic cells observed in shSurv-XG1 cells compared with shCont-XG1 cells, because other mitosis steps such as anaphase could be easily detected. Second, survivin downregulation in XG1 led to the strong increase in polyploid cells (7. 770.8% in shCont-XG1 versus 2571.8% in shSurv-XG1 cells), as detected and quantified by PI staining and flow cytometry analysis (Figure 6a ). This polyploidy was confirmed by the significant increased nuclear size in survivin-depleted cells (10.670.3 mm in shSurv-XG1 versus 8.670.3 mm in shcont-XG1, Po0.001), as detected by Hoechst 33342 staining and depicted in Figure 6d .
Cell cycle was also disrupted in shSurv-XG6 compared with shcont-XG6 but its profile differed from shSurv-XG1. Indeed, shSurv-XG6 cells accumulated in G0/G1 phases (64 versus 47% in shcont-XG6) in the representative experiment shown in Figure  6a and b. G2/M and S phases were concomitantly decreased in shSurv-XG6 cells versus shCont-XG6 cells (7 versus 10% and 29 versus 43% for G2/M and S phases, respectively). Finally, no increase in polyploid cells was detected in shSurv-XG6.
Survivin downregulation sensitized myeloma cells to anti-MM agents
To investigate the impact of survivin on the sensitivity of myeloma cells to conventional drugs used in MM therapy, we analyzed cytotoxic effect of doxorubicin, dexamethasone and melphalan on XG1-and XG6-transduced cells. Interestingly, survivin knockdown significantly enhanced cell viability inhibi- (Figure 7) . Altogether, these results indicate that knocking down survivin in MM cells increased (i) their spontaneous apoptosis and deeply impaired their cell cycle distribution, leading to a marked decrease of their capacity to proliferate and (ii) their sensitivity to conventional anti-MM agents.
Discussion
This work underlines for the first time in our knowledge, the potential role of survivin in myeloma pathogenesis. Indeed, we demonstrated that myeloma cells expressed a high level of survivin and that its depletion by RNA interference inhibited myeloma cell growth and sensitized myeloma cells towards anti-MM agents. First, we observed by immunoblot analysis that all HMCLs display detectable level of survivin comparable to other cancer cells previously described for their survivin overexpression. It was originally thought that the overexpression of survivin observed in cancer simply reflected a higher number of proliferating cells and that survivin expression was mainly cell-cycle-regulated when compared with the canonical CDE/ CDH elements present in survivin gene promoter. 22 But since non-tumoral, highly proliferating EBV-infected B lymphocytes generated from myeloma patients' blood samples express survivin weakly, in comparison with the myeloma cell lines Figure 6 Cell-cycle disruption of shSurv-tranduced HMCLs. Cell cycle in viable shCont and shSurv-XG1 or XG6 cells was monitored by PI staining using flow cytometry and analyzed with MODFIT software (a), and the % of cells in each cell-cycle phase was illustrated in histogram (b). Mitotic cells were evidenced by MGG staining in shCont and shSurv-XG1 cells by using microscopy. An anaphase cell was pointed on shCont-XG1 slide and two prometaphase cells on shSurv-XG1 slide (c). Nuclear size of shCont and shSurv-XG1 cells was evaluated by Hoechst 33342 staining using microcopy (d). A representative experiment is shown (n ¼ 3).
Significant impact of survivin M Romagnoli et al established from the same patients, we propose that survivin level in HMCLs does not reflect exclusively a high proliferating rate but rather a cancer status. This notion is also supported by the observation that survivin level is also higher in HMCLs than in non-tumoral plasma cell precursors, considered as their normal proliferating counterpart. Although myeloma cells usually display a low in vivo proliferation rate, our results showing high levels of survivin in myeloma cells suggest a possible regulation of survivin gene expression in primary myeloma cells independent of cell-cycle progression. These results and others prompt the possibility that survivin gene may be globally deregulated in cancer, driving overexpression of the protein at all cell cycle phases, and not just mitosis. 4, 23 A diversity of events may result in constitutive activation of upstream signalling in cancer cells that may trigger the activation and transcription of appropriate transcription factors to turn on survivin expression in cancer. Of note, Gritsko et al. recently demonstrated that STAT-3 directly regulates the survivin promoter in breast cancer cells. 24 On the contrary, the p53 tumor suppressor has been described as a potent repressor of survivin gene transcription. 25 Further experiments are needed to unravel detailed mechanisms involved in survivin expression control in MM.
Importantly, we show that survivin expression in MM correlated significantly with disease stages. Indeed, survivin levels in patients at diagnosis were significantly lower in comparison with those detected in patients at relapse. Interestingly, we also observed the increase of survivin level in MM cells removed from the same patient at diagnosis and relapse time in his clinical course. Many data currently demonstrate that survivin expression in cancer is associated with unfavorable clinicalpathological parameters, such as poor prognosis and shorter patient survival rates (reviewed by Li 26 ). Of note, regarding hematological malignancies, a significantly shorter survival was observed in patients with high survivin expression in large B-cell lymphoma 27 as well as in mantle cell lymphoma. 28 Moreover, survivin proved to be a negative prognostic factor in patients with acute myeloid leukemia. 29 Our data presented here argue for an increase in survivin level during MM clinical course. In line with our results, a recent report indicates that the expression ratios for survivin were significantly higher in MM patients with poorer outcome, especially after chemotherapy. 30 Although a larger cohort of patients would be necessary to confirm our results (as soon as a reliable survivin mAb for flow cytometry analysis becomes available), our results strongly argue for survivin participation in myeloma progression. However, it would be of particular interest to study survivin involvement in the first steps of oncogenesis in MM. Further experiments delineating survivin expression in normal bone marrow plasma cells and MGUS will be conducted to address this important point.
To define potential interest to inhibit survivin expression in MM cells, we performed RNA interference experiments targeting survivin in both HMCLs XG1 and XG6. The RNA target sequence used here is directed against nucleotides 45-65 of survivin that code for a region common to the three known isoforms of the protein, and was previously used to repress efficiently survivin expression in HeLa cells. 20 On the one hand MM cells are among hard-to-transfect cells and on the other transient RNA interference, using small interfering RNA targeting survivin, decreased the short-lived survivin expression no more than 48 h in our hands (personal data), we developed a lentiviral RNA interference approach. This approach led to efficient transduction of both HMCLs XG1 and XG6, as assessed by GFP monitoring up to 28 days post-transduction and to significant depletion of survivin in these cell lines. These experiments allowed to us to demonstrate that survivin knocking down led to decreased myeloma cell growth rate related to significant increased apoptosis and deep cell cycle disruption.
First, survivin knockdown induced significant spontaneous apoptosis in HMCLs, as detected by Apo2.7 staining or nuclei fragmentation. Our results indicate that survivin knockdown in myeloma cells correlated with caspase-3 and PARP-1 cleavage, arguing for the activation of caspase cascade when survivin level was decreased in these cells. Many in vitro and in vivo experiments show that survivin expression protect cells from cell death (Conway et al. 31 and reviewed by Altieri 2 , Li 3 ). However, elucidation of the mechanisms whereby this occurs has not been straightforward. Actually, the existence of functional survivincaspase complexes initially described is now controversial, as survivin lacks structural motifs that in other IAPs (for example, XIAP) mediated caspase binding. 32 But survivin may mediate apoptosis inhibition through interaction with proapoptotic factors such as the IAP inhibitor SMAC/Diablo, 33 the apoptosis-inducing factor AIF 34 or through subcellular compartmentalization in mitochondria. 35 Whether survivin exerts its inhibitory effect on caspase activity by direct or indirect mechanisms in myeloma cells is currently under investigation.
Second, we observed that survivin depletion caused an accumulation of prometaphase cells and a decline in anaphase and telophase cells in XG1 cell line. In addition, an increased population of shSurv-XG1 cells had a DNA content of 4N or greater compared to shCont-XG1. These observations reveal that Significant impact of survivin M Romagnoli et al survivin knockdown partially blocked normal mitosis progression in MM cells and even if survivin depleted cells eventually exit mitosis, they generally fail to complete cytokinesis. Such cell cycle abnormalities have also been described in melanoma cell lines or HeLa cells. 20, 36 Of note, survivin depletion in XG6 cells also resulted in cell cycle blockade, but with a different profile of DNA content. Indeed, shSurv-XG6 cells accumulated in G1 phase and displayed normal DNA content (no polyploidy). These results support a role for survivin not only in normal mitosis progression and completion but also in early cell cycle entry. The role of survivin in G1/S transition has been proposed in different works even though mechanisms are still completely unresolved. 37, 38 The apparent discrepancy between the stage of cell cycle disruption in shSurv-XG1 and -XG6 cells may also be linked to their different p53 status (mutated p53 in XG1 and wild-type p53 in XG6) (Mazars et al. 39 and unpublished data) as observed by Beltrami et al. 40 in the colorectal carcinoma cell line HCT-116. Indeed, the tumor suppressor p53 maintains the genome integrity and promotes cell cycle checkpoints (both G1/S and G2/M checkpoints) when cells are unable to undergo normal mitosis. Thus, p53 pathway may be activated when XG6 cells were depleted in survivin, leading to elimination of polyploid cells and G1 phase arrest, as initially observed in normal human cells.
41 But other not yet defined mechanisms may be involved and further experiments are needed to delineate the role of p53 in this system.
Finally, survivin depletion in myeloma cells enhanced cytotoxic effect of conventional drugs used in MM therapy, i.e., doxorubicin, dexamethasone and melphalan. Growing evidence has indicated that survivin expression plays an essential role in drug resistance (reviewed Li 3 ). Our data and Nakagawa's report 30 underline this finding in MM and raise the hypothesis that inhibiting survivin may improve MM treatment.
Altogether, these data suggest that survivin might be a rational target for myeloma therapy, since MM expresses high level of the protein survivin and its depletion induces cell growth inhibition and drug sensitization. The use of molecular antagonists, including antisens, ribozymes, siRNA and dominant-negative survivin mutants, have generated promising results in other survivin overexpressing cancers leading to suppression of tumor growth, and provided proof of principle in preclinical testing. Our results argue for the interest in evaluating survivin antagonists in MM treatment. Moreover, our model might help to unravel the complexity of 'survivin network' that appear to intersect multiple pathway of cell division, resistance to apoptosis and surveillance checkpoints.
